Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nageswara Rao Muddana
Observed name:
N.R. Muddana
Institution:
Suven Life Sciences (India)
Observed institutions:
Jawaharlal Nehru Technological University, Hyderabad,
Suven Life Sciences (India)
OpenAlex ID:
A5038345287
Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease
2015
·
Ramakrishna Nirogi
, Abdul Rasheed Mohammed
, et al.
·
European Journal of Medicinal Chemistry
·
67
Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
2021
·
Ramakrishna Nirogi
, Vijay Benade
, et al.
·
Psychopharmacology
·
16
LC–MS/MS method for the quantification of aldose reductase inhibitor – Epalrestat and application to pharmacokinetic study
2012
·
Ramakrishna Nirogi
, Vishwottam Kandikere
, et al.
·
Journal of Pharmaceutical and Biomedical Analysis
·
14
Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy
2020
·
Ramakrishna Nirogi
, Gopinadh Bhyrapuneni
, et al.
·
European Journal of Pharmaceutical Sciences
·
12
Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects
2018
·
Ramakrishna Nirogi
, Koteshwara Mudigonda
, et al.
·
Clinical Drug Investigation
·
11
Skin Sample Preparation by Collagenase Digestion for Diclofenac Quantification Using LC–MS/MS After Topical Application
2016
·
Ramakrishna Nirogi
, Naga Surya Prakash Padala
, et al.
·
Bioanalysis
·
11
Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses
2020
·
Ramakrishna Nirogi
, Koteshwara Mudigonda
, et al.
·
Clinical Drug Investigation
·
9
First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects
2021
·
Ramakrishna Nirogi
, Gopinadh Bhyrapuneni
, et al.
·
Clinical Drug Investigation
·
5
1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition
2021
·
Anil Karbhari Shinde
, Rajesh Kumar Badange
, et al.
·
ChemMedChem
·
4
0053 SUVN-G3031: Safety, Tolerability and Pharmacokinetics of a Potent and Selective Histamine H3 Receptor Inverse Agonist - Single and Multiple Ascending Doses in Healthy Subjects
2019
·
Ramakrishna Nirogi
, Anil Shinde
, et al.
·
SLEEP
·
2
SUVN‐I6107: A novel muscarinic M1 receptor‐positive allosteric modulator (M1‐PAM) for the treatment of cognitive deficits
2020
·
Renny Abraham
, Venkatesh Goura
, et al.
·
Alzheimer s & Dementia
·
1
PDF
[P2–033]: SUVN‐502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION) REPRESENTS A PROMISING NEW APPROACH FOR SYMPTOMATIC TREATMENT OF ALZHEIMER's DISEASE
2017
·
Ramakrishna Nirogi
, Koteshwara Mudigonda
, et al.
·
Alzheimer s & Dementia
·
1
PDF
Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats
2015
·
Pradeep Jayarajan
, Ramakrishna Nirogi
, et al.
·
Behavioural Pharmacology
·
1
Persicaria Minor (Polygonum Minus) Water Extract Protects Against Cartilage Degeneration and Inflammation in a Monoiodoacetate-induced Osteoarthritis Rat Model
2026
·
Sasikala M Chinnappan
, Annie George
, et al.
·
Current Traditional Medicine
Safety, tolerability and pharmacokinetics of a potent and selective histamine h3 receptor inverse agonist, SUVN-G3031 following single and multiple ascending doses in healthy subjects
2019
·
R. Nirogi
, K. Mudigonda
, et al.
·
Sleep Medicine
P2‐031: Safety, Tolerability and Human Pharmacokinetics of Suvn‐502, a Potent and Pure 5‐ht6 Receptor Antagonist
2019
·
Gopinadh Bhyrapuneni
, Vinod Kumar Goyal
, et al.
·
Alzheimer s & Dementia
PDF
[p1–079]: Suvn‐i6107: a Novel Muscarinic M1 Receptor‐positive Allosteric Modulator (m1‐pam) Devoid of Cholinergic Side Effects
2017
·
Pradeep Jayarajan
, Renny Abraham
, et al.
·
Alzheimer s & Dementia
P4–305: SUVN‐512: A novel 5‐HT6 receptor antagonist with drug‐like properties
2013
·
Medapati Rajesh Babu
, Ramakrishna Nirogi
, et al.
·
Alzheimer s & Dementia
Show more works
View as search
Works count:
18
Citation count:
154
H-index:
7
I10-index:
6
Year
Topic
Type